Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00044148
Status:
COMPLETED
Last Update Posted:
2017-02-01
First Post:
2002-08-20
Brief Title:
The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
Sponsor:
Chromaderm Inc
Organization:
Chromaderm Inc
Study Overview
Official Title:
The Effect of LY333531 on Albuminuria in Patients With Type 2 Diabetes A Pilot Clinical Trial
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study are to determine 1 Whether Ly333531 can reduce urinary albumincreatinine excretion in patients with Type II diabetes and persistent albuminuria 2 Whether LY333531 reduces urinary TGF-B 3 the safety of LY333531 and any side effects that may be associated with it
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B7A-MC-MBDA | None | None | None |